Caribou Biosciences, Inc. (CRBU)

Market Cap	449.37M
Revenue (ttm)	10.50M
Net Income (ttm)	-111.20M
Shares Out	88.28M
EPS (ttm)	-1.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,372
Open	5.29
Previous Close	5.26
Day's Range	5.06 - 5.29
52-Week Range	3.96 - 11.52
Beta	1.94
Analysts	Strong Buy
Price Target	24.25 (+376.42%)
Earnings Date	Nov 7, 2023

About CRBU

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 137
• Stock Exchange: NASDAQ
• Ticker Symbol: CRBU

Financial Performance

In 2022, CRBU's revenue was $13.85 million, an increase of 44.31% compared to the previous year's $9.60 million. Losses were -$99.42 million, 48.6% more than in 2021.

Analyst Forecast

According to 4 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price forecast is $24.25, which is an increase of 376.42% from the latest price.

Price Target

$24.25

(376.42% upside)

Analyst Consensus: Strong Buy